HOME
SEARCH
RSS FEED
SUBSCRIBE
Search Results - p
1434
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Com
p
ositions and Methods for Producing Dendritic Cell-based Vaccines with Enhanced Efficacy
Summary: The National Cancer Institute (NCI) is seeking research co-develo
p
ment partners and/or licensees for NCI’s compositions and methods to enhance the efficacy of dendritic cell (DC)-based cancer vaccines. Description of Technology: Current dendritic cell (DC)-based cancer vaccines are limited by impaired DC function due to cancer-driven...
Published: 7/15/2025
|
Inventor(s):
Jay Berzofsky
,
Shweta Tiwary
Keywords(s):
Category(s):
Thera
p
euticArea > Oncology
,
Thera
p
euticArea > Immunology
,
A
p
plication > Therapeutics
,
Collaboration Sought > Collaboration
,
Collaboration Sought > Licensing
Enhanced Tumor Reactivity of T Cells Lacking SIT1, LAX1 or TRAT1
Summary: The Eunice Kennedy Shriver National Institute of Child Health and Human Develo
p
ment (NICHD) is actively seeking potential licensees interested in further developing these inhibitory transmembrane adapter proteins as targets for T-cell immunotherapy for the treatment of cancer, infectious diseases, and autoimmune diseases. Description of Technology: Cellular...
Published: 7/14/2025
|
Inventor(s):
P
aul Love
,
Avik Dutta
Keywords(s):
Category(s):
A
p
plication > Therapeutics
,
Thera
p
euticArea > Oncology
,
Thera
p
euticArea > Immunology
Anti-Nucleo
p
rotein Crimean-Congo Hemorrhagic Fever Virus Monoclonal Antibodies for Assay Creation
Crimean-Congo hemorrhagic fever (CCHF) is the most wides
p
read form of viral hemorrhagic fever, found in Eastern and Southern Europe, the Mediterranean, northwestern China, central Asia, Africa, the Middle East, and the Indian subcontinent. Typically beginning with non-specific fever, myalgia, nausea, diarrhea, and general malaise, symptoms of infection...
Published: 7/3/2025
|
Inventor(s):
Daniel Douek
,
David Hawman
,
Leonid Serebryannyy
,
Noemia Santana Lima
,
Chaim Schramm
,
Sarah Smith (Kerscher)
,
Amy Henry
,
Alicen S
p
aulding
Keywords(s):
Category(s):
A
p
plication
,
A
p
plication > Diagnostics
,
Collaboration Sought
,
Collaboration Sought > Licensing
,
Collaboration Sought > Materials Available
,
Research
P
roducts > Antibodies
,
Thera
p
euticArea
,
Thera
p
euticArea > Infectious Disease
,
Thera
p
euticArea > Immunology
,
Thera
p
euticArea > Rare/Neglected Diseases
Vascularized Thyroid-on-a-Chi
p
for Personalized Drug Screening and Disease Modeling
This technology includes a micro-engineered “thyroid-on-a-chi
p
” that combines human thyroid organoids with integrated micro-vasculature to replicate the gland’s native blood flow and 3-D architecture, enabling rapid, patient-specific drug screening. By permitting real-time perfusion of nutrients, hormones, and immune cells, the platform...
Published: 7/15/2025
|
Inventor(s):
Anagha Rama Varma
,
P
arnika Kant
,
Kaitlyn Sadtler
,
P
arinaz Fathi
,
Nicole Morgan
,
P
aniz Rezvan Sangsari
,
Madison Daminato
Keywords(s):
Category(s):
A
p
plication > Diagnostics
,
A
p
plication > Medical Devices
,
A
p
plication > Research Materials
,
A
p
plication > Therapeutics
,
Research
P
roducts > Human Cell Lines
,
Research
P
roducts > Research Equipment
,
Thera
p
euticArea > Endocrinology
,
Thera
p
euticArea > Immunology
,
Thera
p
euticArea > Metabolic Disease
,
Thera
p
euticArea > Oncology
,
Collaboration Sought > Collaboration
,
Collaboration Sought > Licensing
EV-D68 Monoclonal Antibodies Isolated from Immunized Rhesus Macaques
Enterovirus D68 (EV-D68) has been linked to the wides
p
read outbreaks of respiratory illness and acute flaccid myelitis (AFM) in the United States and Europe in 2014, 2016, and 2018. Although EV-D68 is now the most frequently encountered enterovirus (41.1% of cases), with an estimated global prevalence of 4%, there are no specific, FDA-approved therapeutic...
Published: 7/2/2025
|
Inventor(s):
Tracy Ruckwardt
,
Daniel Moss
,
P
eter Krug
,
Masaru Kanekiyo
Keywords(s):
Category(s):
A
p
plication
,
A
p
plication > Diagnostics
,
A
p
plication > Therapeutics
,
A
p
plication > Vaccines
,
Collaboration Sought
,
Collaboration Sought > Licensing
,
Collaboration Sought > Materials Available
,
Research
P
roducts
,
Research
P
roducts > Antibodies
,
Thera
p
euticArea
,
Thera
p
euticArea > Immunology
,
Thera
p
euticArea > Infectious Disease
Synergistic Interactions for Im
p
roved Cancer Treatment
Summary: The National Cancer Institute (NCI) seeks research co-develo
p
ment partners and/or licensees to develop hetIL-15 in combination with other agents, such as PPARa agonists (Fenofibrate), FLT3 inhibitors (quizartinib), IL-12, or chemotherapy into a therapeutic for cancer. Description of Technology: Immunotherapy has emerged as a promising treatment...
Published: 6/27/2025
|
Inventor(s):
Barbara Felber
,
George
P
avlakis
,
Sevasti Karaliota
,
Dimitrios Stellas
Keywords(s):
Category(s):
Thera
p
euticArea > Immunology
,
Thera
p
euticArea > Oncology
,
A
p
plication > Therapeutics
,
Collaboration Sought > Collaboration
,
Collaboration Sought > Licensing
Establishment and characterization of the A 1847 human ovarian carcinoma line
Summary: The National Cancer Institute (NCI) seeks licensees for a tumorigenic cell line, A1847, from a
p
atient with metastatic ovarian cancer. As a BRCA1 deficient cell line, it serves as a model to researchers studying cell cycle regulation, tumor suppression and effective drugs aiding in repair of DNA damage. Description of Technology: Mutations,...
Published: 6/27/2025
|
Inventor(s):
Stuart Aaronson
,
Nelson Ellmore (Estate)
Keywords(s):
Category(s):
Thera
p
euticArea > Oncology
,
Collaboration Sought > Licensing
,
A
p
plication > Research Materials
Zi
p
14-AAV Genetic MRI Reporter System for Non-Invasive Cell & Gene-Therapy Tracking
This technology includes a gene-based magnetic resonance imaging (MRI) re
p
orter platform that harnesses adeno-associated virus (AAV) delivery of the metal transporter Zip14 to create image contrast wherever the gene is expressed. By driving Zip14 from cell-specific promoters, investigators obtain robust, long-lasting signal changes on standard clinical...
Published: 6/18/2025
|
Inventor(s):
Harikrishna (Hari) Ralla
p
alli
,
Alan Koretsky
,
Raymond (Ray) Fields
Keywords(s):
Category(s):
A
p
plication > Diagnostics
,
A
p
plication > Therapeutics
,
Thera
p
euticArea > Neurology
,
Thera
p
euticArea > Radiology
,
Collaboration Sought > Licensing
Angubindin-1
P
eptide for Transient Blood-Brain Barrier Opening to Boost Chemotherapy in Malignant Glioma
This technology includes a first-in-class synthetic
p
eptide, angubindin-1, designed to temporarily relax the blood-brain barrier (BBB)—the tightly sealed network of brain blood vessel cells that normally blocks most drugs—from the inside. By binding the tricellular tight-junction protein angulin-1/LSR, the peptide creates a reversible “molecular...
Published: 6/13/2025
|
Inventor(s):
Sadhana Jackson
Keywords(s):
Category(s):
A
p
plication > Therapeutics
,
Thera
p
euticArea > Neurology
,
Thera
p
euticArea > Oncology
,
Collaboration Sought > Licensing
Oral Iron-Chelator Thera
p
y for Treating Developmental Stuttering
This technology discloses the use of small-molecule iron chelators—drugs that bind and remove excess iron—for the oral treatment of develo
p
mental stuttering in children and adults. Mouse models carrying human stuttering mutations show both elevated striatal iron and impaired vocalization; daily low-dose deferiprone reverses these speech-like...
Published: 6/13/2025
|
Inventor(s):
Shahriar SheikhBahaei
Keywords(s):
Category(s):
A
p
plication > Therapeutics
,
Thera
p
euticArea > Neurology
,
Thera
p
euticArea > Psychiatry/Mental Health
,
Collaboration Sought > Licensing
1
2
3
4
5
6
7
8
9
10
...
Home
|
Search
|
RSS
|
Subscribe
© 2025. All Rights Reserved. Powered by
Inteum